$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

$eltp Overview Financials Valuation SEC Filings Company Website

2014 Q3 Form 10-Q Financial Statement

#000114420414050155 Filed on August 14, 2014

Income Statement

Concept	2014 Q3	2014 Q2	2013 Q2
Revenue	$1.256M	$1.162M	$722.0K
YoY Change	8.37%	60.94%	24.79%
Cost Of Revenue	$682.0K	$729.0K	$579.0K
YoY Change	10.53%	25.91%	27.43%
Gross Profit	$575.0K	$433.0K	$143.0K
YoY Change	6.09%	202.8%	15.14%
Gross Profit Margin	45.78%	37.26%	19.81%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development	$3.584M	$4.020M
YoY Change	319.24%
% of Gross Profit	623.23%	928.48%
Depreciation & Amortization	$230.0K	$209.4K	$109.6K
YoY Change	109.09%	91.14%	-7.5%
% of Gross Profit	40.0%	48.36%	76.61%
Operating Expenses	$4.636M	$4.864M	$1.118M
YoY Change	277.22%	335.06%	83.29%
Operating Profit	-$4.061M	-$4.431M	-$976.0K
YoY Change	491.12%	354.0%	100.92%
Interest Expense	$70.08K	$78.21K	$74.78K
YoY Change	-72.62%	4.58%	27.74%
% of Operating Profit
Other Income/Expense, Net	$10.31M	$2.338M	$2.095M
YoY Change	-249.7%	11.6%
Pretax Income	$21.38M	-$4.402M	$921.7K
YoY Change	-321.89%	-577.59%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income	0.0%		0.0%
Net Earnings	$6.248M	-$2.094M	$922.0K
YoY Change	-164.83%	-327.11%	-108.76%
Net Earnings / Revenue	497.45%	-180.21%	127.7%
Basic Earnings Per Share	$0.04	-$0.01	$0.00
Diluted Earnings Per Share	-$0.01	-$0.01	$0.00
COMMON SHARES
Basic Shares Outstanding	577.7M shares	565.2M shares	388.0M shares
Diluted Shares Outstanding	739.9M shares	733.9M shares	580.4M shares

Balance Sheet

Concept	2014 Q3	2014 Q2	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.630M	$8.170M	$230.0K
YoY Change	890.91%	3452.17%	-52.08%
Cash & Equivalents	$7.627M	$8.173M	$231.1K
Short-Term Investments
Other Short-Term Assets	$460.0K	$220.0K	$120.0K
YoY Change	187.5%	83.33%	50.0%
Inventory	$2.520M	$2.530M	$938.6K
Prepaid Expenses
Receivables	$1.100M	$1.170M	$499.1K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$11.71M	$12.08M	$1.785M
YoY Change	257.15%	576.74%	25.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.170M	$4.950M	$3.958M
YoY Change	31.21%	25.05%	-5.53%
Goodwill
YoY Change
Intangibles			$712.9K
YoY Change
Long-Term Investments	$40.00K	$20.00K	$3.340M
YoY Change	-98.8%	-99.4%	0.0%
Other Assets	$610.0K	$584.9K	$590.0K
YoY Change	12.96%	-0.86%	1.72%
Total Long-Term Assets	$12.18M	$11.89M	$8.607M
YoY Change	-13.82%	38.12%	-1.86%
TOTAL ASSETS
Total Short-Term Assets	$11.71M	$12.08M	$1.785M
Total Long-Term Assets	$12.18M	$11.89M	$8.607M
Total Assets	$23.89M	$23.97M	$10.39M
YoY Change	37.2%	130.64%	1.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.680M	$3.210M	$1.280M
YoY Change	38.86%	150.78%	-2.29%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$670.0K	$620.0K	$0.00
YoY Change	-89.5%
Long-Term Debt Due	$334.9K	$3.480M	$3.990M
YoY Change	-90.12%	-12.78%	17.35%
Total Short-Term Liabilities	$3.810M	$7.310M	$5.310M
YoY Change	-67.5%	37.66%	11.56%
LONG-TERM LIABILITIES
Long-Term Debt	$233.8K	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$73.38M	$101.1M	$93.82K
YoY Change	76275.44%	107667.9%	-99.67%
Total Long-Term Liabilities	$75.45M	$101.1M	$11.48M
YoY Change	553.74%	780.59%	-60.1%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.810M	$7.310M	$5.310M
Total Long-Term Liabilities	$75.45M	$101.1M	$11.48M
Total Liabilities	$79.25M	$108.4M	$16.79M
YoY Change	240.66%	545.65%	-49.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$208.0M		-$127.5M
YoY Change	51.68%
Common Stock	$153.0M		$121.4M
YoY Change	16.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$306.8K		$306.8K
YoY Change	0.0%
Treasury Stock Shares	100.0K shares	100.0K shares	100.0K shares
Shareholders Equity	-$55.36M	-$84.45M	-$6.400M
YoY Change
Total Liabilities & Shareholders Equity	$23.89M	$23.97M	$10.39M
YoY Change	37.2%	130.66%	1.98%

Cashflow Statement

Concept	2014 Q3	2014 Q2	2013 Q2
OPERATING ACTIVITIES
Net Income	$6.248M	-$2.094M	$922.0K
YoY Change	-164.83%	-327.11%	-108.76%
Depreciation, Depletion And Amortization	$230.0K	$209.4K	$109.6K
YoY Change	109.09%	91.14%	-7.5%
Cash From Operating Activities	-$4.430M	-$4.210M	-$355.0K
YoY Change	381.52%	1085.76%	19.39%
INVESTING ACTIVITIES
Capital Expenditures	-$320.0K	-$690.0K	-$50.00K
YoY Change	255.56%	1280.0%	150.0%
Acquisitions
YoY Change
Other Investing Activities	-$50.00K	$4.930M	-$80.00K
YoY Change	-200.0%	-6262.5%	60.0%
Cash From Investing Activities	-$380.0K	$4.240M	-$134.9K
YoY Change	660.0%	-3243.37%	87.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$896.6K	$400.0K
YoY Change		124.15%
Debt Paid & Issued, Net	$915.0K
YoY Change
Cash From Financing Activities	4.260M	1.200M	$352.0K
YoY Change	182.12%	240.9%	100.04%
NET CHANGE
Cash From Operating Activities	-4.430M	-4.210M	-$355.0K
Cash From Investing Activities	-380.0K	4.240M	-$134.9K
Cash From Financing Activities	4.260M	1.200M	$352.0K
Net Change In Cash	-550.0K	1.230M	-$137.9K
YoY Change	-201.85%	-991.81%	-28.67%
FREE CASH FLOW
Cash From Operating Activities	-$4.430M	-$4.210M	-$355.0K
Capital Expenditures	-$320.0K	-$690.0K	-$50.00K
Free Cash Flow	-$4.110M	-$3.520M	-$305.0K
YoY Change	395.18%	1053.92%	9.97%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q1	us-gaap	Assets Current AssetsCurrent	9924763	USD
CY2014Q1	us-gaap	Cost Method Investments CostMethodInvestments	3329322	USD
CY2014Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	565150231	shares
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6941777	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8172966	USD
CY2014Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	732076	USD
CY2014Q1	us-gaap	Inventory Net InventoryNet	1932486	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	318424	USD
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	921666	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4401810	USD
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1223977	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4401810	USD
CY2013Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	387969981	shares
CY2014Q2	us-gaap	Cost Method Investments CostMethodInvestments	0	USD
CY2014Q2	us-gaap	Security Deposit SecurityDeposit	16314	USD
CY2014Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	339402	USD
CY2014Q2	us-gaap	Deferred Offering Costs DeferredOfferingCosts	229211	USD
CY2014Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	584927	USD
CY2014Q2	us-gaap	Assets Assets	23968291	USD
CY2014Q1	eltp	Short Term Loans And Current Portion Of Long Term Debt ShortTermLoansAndCurrentPortionOfLongTermDebt	18870	USD
CY2014Q2	eltp	Short Term Loans And Current Portion Of Long Term Debt ShortTermLoansAndCurrentPortionOfLongTermDebt	90250	USD
CY2014Q2	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	617064	USD
CY2014Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2214871	USD
CY2014Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3206314	USD
CY2014Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13333	USD
CY2014Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13333	USD
CY2014Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6349922	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4199602	USD
CY2014Q2	us-gaap	Secured Debt Current SecuredDebtCurrent	3385000	USD
CY2014Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	134083	USD
CY2014Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	111404	USD
CY2014Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5508377	USD
CY2014Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5713939	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	USD
CY2014Q1	eltp	Accumulated Amortization Eda Bond Offering Costs AccumulatedAmortizationEdaBondOfferingCosts	121697	USD
CY2014Q2	eltp	Accumulated Amortization Eda Bond Offering Costs AccumulatedAmortizationEdaBondOfferingCosts	125242	USD
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	690000000	shares
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	995000000	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	560242430	shares
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	568042073	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	560142430	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	567972073	shares
CY2014Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
CY2014Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
CY2013Q2	us-gaap	License And Services Revenue LicenseAndServicesRevenue	173255	USD
CY2014Q2	us-gaap	License And Services Revenue LicenseAndServicesRevenue	207645	USD
CY2013Q2	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	1899	USD
CY2013Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-419522	USD
CY2013Q2	eltp	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	-34833	USD
CY2013Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-43061	USD
CY2013Q2	eltp	Increase Decrease In Deferred Revenue And Customer Deposits IncreaseDecreaseInDeferredRevenueAndCustomerDeposits	-3333	USD
CY2013Q2	eltp	Increase Decrease In Derivative Interest Payable Net IncreaseDecreaseInDerivativeInterestPayableNet	-3916	USD
CY2013Q2	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	35561	USD
CY2014Q2	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	6611	USD
CY2014Q2	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	74359	USD
CY2014Q2	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	11498	USD
CY2013Q2	us-gaap	Interest Paid InterestPaid	13962	USD
CY2014Q2	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	5000000	USD
CY2013Q2	eltp	Interest Expense Preferred Share Derivatives InterestExpensePreferredShareDerivatives	23584	USD
CY2014Q2	eltp	Interest Expense Preferred Share Derivatives InterestExpensePreferredShareDerivatives	0	USD
CY2013Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1897258	USD
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	29464	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	921666	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4401810	USD
CY2013Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-4401810	USD
CY2013Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2013Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2013Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	580388867	shares
CY2014Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	733912128	shares
CY2013Q2	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	351	USD
CY2014Q2	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	373	USD
CY2014Q2	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4212663	USD
CY2014Q2	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	678811	USD
CY2013Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-166071	USD
CY2014Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	434673	USD
CY2014Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	593429	USD
CY2014Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	896613	USD
CY2014Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23662	USD
CY2014Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	9358	USD
CY2013Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	109553	USD
CY2014Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	209395	USD
CY2013Q2	us-gaap	Paid In Kind Interest PaidInKindInterest	27500	USD
CY2014Q2	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
CY2014Q2	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-2387	USD
CY2014Q2	eltp	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	-102513	USD
CY2014Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	540177	USD
CY2014Q2	eltp	Increase Decrease In Deferred Revenue And Customer Deposits IncreaseDecreaseInDeferredRevenueAndCustomerDeposits	-3334	USD
CY2014Q2	eltp	Increase Decrease In Derivative Interest Payable Net IncreaseDecreaseInDerivativeInterestPayableNet	0	USD
CY2013Q2	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-355047	USD
CY2013Q2	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	18496	USD
CY2013Q2	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	80830	USD
CY2014Q2	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	4240218	USD
CY2013Q2	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2014Q2	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	239564	USD
CY2013Q2	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	0	USD
CY2014Q2	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	88314	USD
CY2013Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	400000	USD
CY2014Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	896613	USD
CY2013Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	47987	USD
CY2014Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9360	USD
CY2013Q2	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	352013	USD
CY2014Q2	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1203633	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	150540	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-137921	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1231189	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	369023	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	231102	USD
CY2014Q2	us-gaap	Interest Paid InterestPaid	77832	USD
CY2013Q2	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2014Q2	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2013Q2	eltp	Commitment Shares Issued CommitmentSharesIssued	219296	USD
CY2014Q2	eltp	Commitment Shares Issued CommitmentSharesIssued	653264	USD
CY2013Q2	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	962436	USD
CY2014Q2	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
CY2014Q2	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	272727	USD
CY2014Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	0	USD
CY2014Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	0	USD
CY2014Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	409145	USD
CY2014Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	421058	USD
CY2014Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1523341	USD
CY2014Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	2104857	USD
CY2014Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	USD
CY2014Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	85344	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	65196	USD
CY2013Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	22584	USD
CY2014Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	18817	USD
CY2014Q1	us-gaap	Deferred Rent Credit DeferredRentCredit	18824	USD
CY2014Q2	us-gaap	Deferred Rent Credit DeferredRentCredit	16437	USD
CY2013Q2	eltp	Accrued Compensation Non Cash AccruedCompensationNonCash	0	USD
CY2014Q2	eltp	Accrued Compensation Non Cash AccruedCompensationNonCash	451271	USD
CY2014Q2	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	1670678	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	0	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	0	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	0	USD
CY2014Q2	us-gaap	Income Tax Credits And Adjustments IncomeTaxCreditsAndAdjustments	-3248	USD
CY2013Q2	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	0	USD
CY2014Q2	dei	Document Type DocumentType	10-Q
CY2014Q2	dei	Amendment Flag AmendmentFlag	false
CY2014Q2	dei	Document Period End Date DocumentPeriodEndDate	2014-06-30
CY2014Q2	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2014Q2	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q2	dei	Entity Registrant Name EntityRegistrantName	ELITE PHARMACEUTICALS INC /NV/
CY2014Q2	dei	Entity Central Index Key EntityCentralIndexKey	0001053369
CY2014Q2	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2014Q2	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2014Q2	dei	Trading Symbol TradingSymbol	ELTP
CY2014Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	574665121	shares
CY2014Q2	eltp	Stock Issued During Period Value Issued For Capital Purchase Agreement StockIssuedDuringPeriodValueIssuedForCapitalPurchaseAgreement	0	USD
CY2014Q2	eltp	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	239564	USD
CY2014Q2	us-gaap	Description Of Lessee Leasing Arrangements Operating Leases DescriptionOfLesseeLeasingArrangementsOperatingLeases	initial term of 5 years and 6 months and the Company has the option to renew the lease for two additional terms, each of 5 years
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2165666	shares
CY2014Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	3870001	shares
CY2014Q3	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	915000	USD
CY2013Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	192418886	shares
CY2014Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares

Files In Submission

Name	View Source	Status
0001144204-14-050155-index-headers.html	Edgar Link	pending
0001144204-14-050155-index.html	Edgar Link	pending
0001144204-14-050155.txt	Edgar Link	pending
0001144204-14-050155-xbrl.zip	Edgar Link	pending
eltp-20140630.xml	Edgar Link	completed
eltp-20140630.xsd	Edgar Link	pending
eltp-20140630_cal.xml	Edgar Link	unprocessable
eltp-20140630_def.xml	Edgar Link	unprocessable
eltp-20140630_lab.xml	Edgar Link	unprocessable
eltp-20140630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v386272_10q.htm	Edgar Link	pending
v386272_ex31-1.htm	Edgar Link	pending
v386272_ex31-2.htm	Edgar Link	pending
v386272_ex32-1.htm	Edgar Link	pending
v386272_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2014 Q3 Form 10-Q Financial Statement

#000114420414050155 Filed on August 14, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2014 Q3 Form 10-Q Financial Statement

#000114420414050155 Filed on August 14, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp